FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease

News & Record Life

Jun 20, 2022

MONDAY, June 20, 2022 (HealthDay News) -- Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to s…